Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qsymia in Bulimia Nervosa and Binge Eating Disorder
NCT02553824Phase 1Completed
- Sponsor
- Stanford University
- Start
- Oct 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of phentermine + topiramate in bulimia nervosa (BN) and binge eating disorder (BED), sponsored by Stanford University. Primary endpoint: Frequency of binge eating episodes at 8.5 months. Started Oct 2015; status: completed.
02
Drugs
phentermine + topiramate
03
Conditions
bulimia nervosa (BN)binge eating disorder (BED)
Beyond the preview
Go deeper on NCT02553824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553824.